579 results on '"Gribben J"'
Search Results
2. Short and long-term acceptability and efficacy of extended-release cornstarch in the hepatic glycogen storage diseases: results from the Glyde study
3. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus
4. Adipocytes disrupt the translational programme of acute lymphoblastic leukaemia to favour tumour survival and persistence
5. TARGETING THE DEFECTIVE COA PATHWAY TO IMPROVE ERYTHROPOIESIS IN SF3B1-MUTANT MDS-RS PATIENTS
6. Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL
7. Life expectancy of young adults with follicular lymphoma
8. O20 - TARGETING THE DEFECTIVE COA PATHWAY TO IMPROVE ERYTHROPOIESIS IN SF3B1-MUTANT MDS-RS PATIENTS
9. Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party
10. Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial
11. The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party
12. Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo
13. Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes
14. S145: THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS IN A HIGH RATE OF MRD NEGATIVITY IN PREVIOUSLY UNTREATED CLL: THE RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE PHASE III NCRI FLAIR TRIAL
15. P405: INHIBITION OF CKS1-DEPENDENT PROTEOSTASIS REVEALS VULNERABILITIES IN LEUKAEMIC STEM CELLS WITH CONCOMITANT PROTECTION OF HEALTHY HAEMATOPOIETIC STEM CELLS
16. S206: OBINUTUZUMAB PLUS CHEMOTHERAPY DEMONSTRATES LONG-TERM BENEFIT OVER RITUXIMAB PLUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: FINAL ANALYSIS OF THE GALLIUM STUDY
17. P1411: DUAL EPIGENETIC AND GENETIC EDITING OF PRIMARY HUMAN HAEMATOPOIETIC STEM AND PROGENITOR CELLS
18. Successful Purging of Stem Cell Products Using CD34 Selection
19. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus
20. Genetic and phenotypic characterization of HIV-associated aggressive B-cell non-Hodgkin lymphomas, that do not occur specifically in this population: diagnostic and prognostic implications
21. Minimal residual disease analysis in patients with follicular lymphoma treated with obinutuzumab plus bendamustine versus bendamustine alone in GADOLIN, a phase III study of relapsed/refractory indolent non-Hodgkin lymphoma: 224
22. Enhanced activation of an amino-terminally truncated isoform of voltage-gated proton channel HVCN1 enriched in malignant B cells: OS1-04
23. Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome
24. OUTCOMES IN LATER‐LINES OF THERAPY FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: RESULTS FROM THE INTERNATIONAL SCHOLAR‐5 STUDY
25. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia
26. EZH2 Y641 mutations in follicular lymphoma
27. Trisomy 12 chronic lymphocytic leukaemia cells exhibit functional upregulation of integrin signalling that is modulated by NOTCH1 mutations: 38
28. Ofatumumab + chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted): 37
29. Lenalidomide potentiates human T cell alloresponses by selectively increasing proliferation of alloreactive CD8+ cells which exhibit a novel gene expression profile - implications for IMiD therapy after allogeneic haematopoietic stem cell transplant: 32
30. Results of the randomised phase II NCRI ADMIRE trial of FC-R and FCM-R in previously untreated CLL: oral FCR is highly effective and safe but the addition of mitoxantrone does not improve responses: 34
31. Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukaemia: 30
32. Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL): 3
33. Array-based DNA methylation profiling in follicular lymphoma
34. REDUCED INTENSITY ALLOGENEIC TRANSPLANTATION IN MULTIPLE MYELOMA: PH-P522
35. LENALIDOMIDE POTENTIATES HUMAN T CELL ALLORESPONSES BY SELECTIVELY INCREASING PROLIFERATION OF ALLOREACTIVE CD8+ CELLS WHICH EXHIBIT A NOVEL GENE EXPRESSION PROFILE - IMPLICATIONS FOR IMID THERAPY AFTER ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANT: PH-P439
36. Gene Expression Profiling of B Cell Lymphoma in Dogs Reveals Dichotomous Metabolic Signatures Distinguished by Oxidative Phosphorylation
37. HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation
38. The evolving role of Alemtuzumab in management of patients with CLL
39. Prognostic impact of p27KIP1 expression in cyclin D1 positive lymphoproliferative disorders
40. CKS1-dependent proteostatic regulation has dual roles combating acute myeloid leukemia whilst protecting normal hematopoiesis
41. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect
42. Ex vivo B cell depletion using the Eligix B Cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma
43. Genetics of teenage and young adult t-cell acute lymphoblastic leukaemia: 168
44. Frequency of leukemic initiating cells does not depend on the xenotransplantation model used
45. Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia
46. Final response assessment of the CLL208 trial: an open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukaemia (CLL).: 43
47. An open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukaemia (CLL): On behalf of the NCRI CLL sub-group: 3
48. CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma
49. The Microenvironment Differentially Impairs Passive and Active Immunotherapy in B-CLL - Potential Therapeutic Synergism of CXCR4 Antagonists: V552
50. Array-based DNA methylation profiling in follicular lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.